trending Market Intelligence /marketintelligence/en/news-insights/trending/aYjp4tk4qf5za6tELoiEvA2 content esgSubNav
In This List

Celgene's bowel disease treatment demonstrates efficacy in phase 2 trials

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Celgene's bowel disease treatment demonstrates efficacy in phase 2 trials

Celgene Corp. said its anti-inflammatory drug Ozanimod, or RPC1063, showed benefit in patients with Crohn's disease and ulcerative colitis.

In the phase 2 STEPSTONE study, 43% of the patients using Ozanimod saw a 25% decrease in Crohn's disease, while 27% of patients saw a reduction of 50% after 12 weeks.

In the phase 2 TOUCHSTONE study, 91% of ulcerative colitis patients at week 92 had little or no active disease. The most common adverse effects were ulcerative colitis flare, anemia, upper respiratory tract infection and back pain.

The results will be presented at the 2017 World Congress of Gastroenterology in Orlando, Fla.